Company to host conference call and webcast on Thursday , November 17 th at 8:30 am EDT LYON, France, November 2 , 20 2 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended

Generated Q3 2022 total revenue of approximately EUR 12.2 million (USD 12.3 million), an increase of 29.7 % as compared to EUR 9.4 million (USD 11.1 million) for Q3 2021; nine-month year-to-date revenue increased 30.9% compared to the same period in 2021 Generated HIFU sales of EUR $3.5 million

LYON, France, November 21, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that Marc Oczachowski, Chief Executive Officer, is scheduled to deliver a company presentation and host investor 1x1 meetings at the Piper Sandler 34 th

  Study to begin enrolling patients in Q2 2023   Endometriosis represents significant expansion opportunity for Focal One  LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has

LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the

Company preliminarily reports nine Focal One Placements in the U.S. , including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company experienced robust demand for its Focal One

Focal One ® HIFU treatment resulted in significant improvements in endometriosis symptoms  and quality of life (QoL) Positive safety profile with 9 6 . 7 % of patients with no or non- significant adverse events Data was presented at the Paris Santé Femmes Major Gynecology French Congress on Friday,

Record f ull-year 2022 total preliminary unaudited revenue of €55.1 million ($58 .0 million) represents an increase of 25. 1 % over full-year 2021, driven by 58.1% HIFU growth R ecord Q4 2022 total preliminary unaudited revenue of €15. 8 million ($16. 2 million) versus €14.0 million ($15.9 million)

LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30 th ,

  Results demonstrate s alvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU -treated arm versus 86.8% in patients who underwent r adical p rostatectomy (RP) The HIFU treated arm showed significant benefits across multiple side effect and quality-of-life measures LYON,